不同Ki67表达的浸润性乳腺癌临床特征分析

Clinical features of invasive breast cancer with different Ki67 expression

关键词:  浸润性乳腺癌  预后

Key words:  invasive breast cancer  prognosis

摘要:

目的　对比分析不同Ki67表达的浸润性乳腺癌的临床特征，探讨Ki67与各预后参数的关系。　方法　回顾性分析2015年1月至2017年12月期间行手术治疗的浸润性乳腺癌患者315例，根据Ki67表达高低分组，分为低表达组（Ki67≤14%）及高表达组（Ki67＞14%），其中低表达组178例，高表达组137例。对两组患者的各预后参数进行记录、总结，包括肿物大小、转移淋巴结情况、组织学分级、ER表达、PR表达、HER-2表达及分子分型情况，分析上述参数在两组中的差异。　结果　两组患者的淋巴结转移情况对比差异没有统计学意义（P＞0.05），两组患者的肿瘤大小、组织学分级、ER表达、PR表达、HER-2表达及分子分型情况方面存在统计学差异（P＜0.05）。　结论　不同Ki67表达的浸润性乳腺癌临床特征具有一定差异。Ki67可以在浸润性乳腺癌中作为判断预后的指标，并有助于治疗决策的制定。

Abstract:

Objective To compare the clinical features of invasive breast cancer with different Ki67 expression and to explore the relationship between Ki67 expression and various prognostic parameters. Methods Totally 315 patients with invasive breast cancer, who underwent surgery in our hospital, were enrolled. According to the Ki67 expression level, they were divided into low expression group (Ki67≤14%) and high expression group (Ki67>14%). The prognostic parameters of the two groups were recorded and summarized, including tumor size, lymph node metastasis, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype. Results There was no significant difference in lymph node metastasis between the two groups (P>0.05). There were significant differences on tumor size, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype (P<0.05). Conclusion The clinical features of invasive breast cancer with different Ki67 expression are different. Ki67 can be used in invasive breast cancer as an indicator to obtain prognostic information and may help for therapeutic decisions.